3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Ovarian Neoplasms
60
Breast Neoplasms
21
Neoplasms
19
Fallopian Tube Neoplasms
16
Prostatic Neoplasms
15
Neoplasm Metastasis
9
Pancreatic Neoplasms
8
Endometrial Neoplasms
8
Glioblastoma
7
Triple Negative Breast Neoplasms
6
Lung Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Small Cell Lung Carcinoma
4
Glioma
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Mesothelioma
3
Melanoma
3
Head and Neck Neoplasms
3
Cystadenocarcinoma, Serous
3
Cholangiocarcinoma
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Urogenital Neoplasms
2
Stomach Neoplasms
2
Solid Tumor
2
Sarcoma
2
Prostatic Neoplasms, Castration-Resistant
2
Ovarian Diseases
2
Mesothelioma, Malignant
2
Interventions
Gemcitabine
13
Albumin-Bound Paclitaxel
8
Taxes
6
130-nm albumin-bound paclitaxel
6
Fluorouracil
5
Oxaliplatin
4
dehydroftorafur
3
Radiotherapy, Intensity-Modulated
3
Radiotherapy
3
Leucovorin
3
Irinotecan
3
Losartan
2
Cisplatin
2
tocilizumab
1
selicrelumab
1
niraparib
1
irinotecan sucrosofate
1
indusatumab
1
folfirinox
1
durvalumab
1
cobimetinib
1
atezolizumab
1
X-Rays
1
Tiragolumab
1
Surgical Procedures, Operative
1
Standard of Care
1
Specimen Handling
1
S 1 (combination)
1
Resistance Training
1
Radiotherapy, Image-Guided
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pancreatic Adenocarcinoma
×
niraparib
×
Clear all
NCT03404960
2025-10-10
Parpvax
University of Pennsylvania
Phase 1/2
Completed
104 enrolled
11 charts